In this webinar, Jeff Blaney (Senior Director of Discovery Chemistry, Genentech), Darren Green (Head of Cheminformatics & Data Science, GlaxoSmithKline), Julian Levell (Head of Discovery, New Equilibrium Biosciences), and Matthew Segall (CEO, Optibrium) discuss the state of AI in early drug discovery from hit to preclinical candidate.

The group share their experiences with and expectations of AI, including predictive modelling, synthesis prediction, and generative chemistry.

Hear about the successes of AI drug discovery and an outlook on what AI needs to achieve to really transform the industry.​

More AI-guided discovery resources